Brain News and Research

RSS

The human brain is the center of the human nervous system and is a highly complex organ. Enclosed in the cranium, it has the same general structure as the brains of other mammals, but is over three times as large as the brain of a typical mammal with an equivalent body size.

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

Curis, Inc., announced today that its licensee Debiopharm S.A. has received approval from France's regulatory authority Agence Française de Securité Sanitaire des Produits de Santé (AFSSAPS) of a Clinical Trial Application (CTA) for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305. Under the terms of Curis’ and Debiopharm’s August 2009 license agreement, Curis will receive an $8 million milestone payment from Debiopharm for the achievement of this development objective.

12 Feb 2010

New research finds sensory cortex develops late in fragile X syndrome defect

Why do people with fragile X syndrome, a genetic defect that is the best-known cause of autism and inherited mental retardation, recoil from hugs and physical touch - even from their parents?

12 Feb 2010

Viral Genetics: Company update

Our mission is to bring new drug compounds to the marketplace. And we've never been in a stronger position to deliver on that promise. We've built the solid foundation needed to take drug therapies from the laboratory to the marketplace. After years in development, we believe several of our most promising compounds are moving closer to clinical trials.

12 Feb 2010

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that it has hired MTS Health Partners, L.P. as strategic advisor to complement and augment the company’s ongoing business development activities.

12 Feb 2010

Data demonstrates the effectiveness of NeuroAiD on neuronal and brain injuries

The January issue of "Neuropharmacology", publishes the article entitled "Neuroprotective and Neuroproliferative Activities of NeuroAiD", reporting pharmacological data establishing NeuroAiD (MLC 601) protective effects on neuronal and brain injuries as well as its effectiveness in neurological functions recovery.

12 Feb 2010

Anti-PC antibody linked to reduced risk of arteriosclerosis

The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The researchers hope to be able to develop a vaccine that can mobilise the body's own defence against arteriosclerosis and stroke.

12 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

Researchers develop dietary supplement to offset key symptom of ageing

Researchers at McMaster University have developed a cocktail of ingredients that forestalls major aspects of the aging process.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

SSA to add early-onset Alzheimer's disease to its Compassionate Allowances Initiative

In its effort to improve and expedite the disability determination process, the Social Security Administration has announced that it will add early-onset Alzheimer's disease to its Compassionate Allowances Initiative. The initiative identifies debilitating diseases and medical conditions that meet the SSA's disability standards for Social Security Disability Income (SSDI) or Supplemental Security Income (SSI).

12 Feb 2010

Social Security Administration adds early-onset Alzheimer's disease to Compassionate Allowances list: AFA lauds

The Alzheimer's Foundation of America (AFA) today applauded the Social Security Administration for including early-onset Alzheimer's disease among the medical conditions that will be given automatic approval for disability benefits, rather than have individuals go through what could be a lengthy qualification process.

12 Feb 2010

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

IBM today announced a Research collaboratory in Melbourne, Australia, where scientists from the Victorian Life Sciences Computational Initiative at the University of Melbourne and the IBM Research Computational Biology Center will use high performance computing – including IBM's Blue Gene supercomputer – to study human disease.

12 Feb 2010

AMC receives GWTG-Stroke Gold Performance Achievement Award for caring stroke patients

Adventist Medical Center recently received the American Heart Association/American Stroke Association's Get With The Guidelines (GWTG) - Stroke Gold Performance Achievement Award. The award recognizes AMC's commitment and success in implementing a higher standard of stroke care by ensuring that stroke patients receive treatment according to nationally accepted standards and recommendations provided by the AHA/ASA.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

Cancer drug could be effective for treating recurrent nose bleeds

Patients suffering from hereditary hemorrhagic telangiectasia (HHT), an inherited vascular condition characterized by profuse nosebleeds, may find hope in a cancer-fighting drug called bevacizumab, also known as Avastin.

12 Feb 2010

Study could lead to new ways to combat obesity

The tiny tongue of a fruit fly could provide big answers to questions about human eating habits, possibly even leading to new ways to treat obesity, according to a study from a team of Texas A&M University researchers.

12 Feb 2010

First FDA-approved umbilical cord blood stem cells infusion trial in children with cerebral palsy

Medical College of Georgia researchers are conducting the first FDA-approved clinical trial to determine whether an infusion of stem cells from umbilical cord blood can improve the quality of life for children with cerebral palsy.

12 Feb 2010

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.

11 Feb 2010

Critical phases of brain development may be mistimed in autistic patients, says study

Research into Fragile X Syndrome - a genetic condition that is the leading known cause of autism - has discovered that critical phases in the brain's development may be mistimed in people with the condition.

11 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Brain News and Research

Further Reading

Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis

New research finds sensory cortex develops late in fragile X syndrome defect

Viral Genetics: Company update

Neurologix hires MTS Health Partners, L.P. as strategic advisor to augment business development activities

Data demonstrates the effectiveness of NeuroAiD on neuronal and brain injuries

Anti-PC antibody linked to reduced risk of arteriosclerosis

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Researchers develop dietary supplement to offset key symptom of ageing

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

SSA to add early-onset Alzheimer's disease to its Compassionate Allowances Initiative

Social Security Administration adds early-onset Alzheimer's disease to Compassionate Allowances list: AFA lauds

IBM, VLSCI scientists to use Blue Gene supercomputer to study human disease

AMC receives GWTG-Stroke Gold Performance Achievement Award for caring stroke patients

Second-quarter fiscal 2010 results announced by Pharmacyclics

Cancer drug could be effective for treating recurrent nose bleeds

Study could lead to new ways to combat obesity

First FDA-approved umbilical cord blood stem cells infusion trial in children with cerebral palsy

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Critical phases of brain development may be mistimed in autistic patients, says study

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News